Pregled bibliografske jedinice broj: 6221
An assesment of quantitative ELISA Pyloriset EIA-G in monitoring of Helicobacter pylori eradication
An assesment of quantitative ELISA Pyloriset EIA-G in monitoring of Helicobacter pylori eradication // The official publication of Medlab 97 : Abstracts / Vonderschmitt, Dieter J. (ur.).
Basel: Degra AG, Werbung/Marketing-Services, Rotkreuz, 1997. str. 230-230 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 6221 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
An assesment of quantitative ELISA Pyloriset EIA-G in monitoring of Helicobacter pylori eradication
Autori
Antoljak, Nataša ; Vukadinović, Marija Vesna ; Zubčić, Ana ; Topić, Elizabeta
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
The official publication of Medlab 97 : Abstracts
/ Vonderschmitt, Dieter J. - Basel : Degra AG, Werbung/Marketing-Services, Rotkreuz, 1997, 230-230
Skup
12th IFCC Eueopean Congress of Clinical Chemistry
Mjesto i datum
Basel, Švicarska, 17.08.1997. - 22.08.1997
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Helicobacter pylori; gastric mucosa inflammation; chronic superficial gastritis; peptic ulceration; ELISA; Pyloriset EIA-G
Sažetak
Helicobacter pylori (HP) infection results in inflammation of the gastric mucosa, termed chronic superficial gastritis, developing peptic ulceration in some patients. Proper treatment includes eradication of the causative microorganism. To monitor the efficacy of anti-HP treatment, the noninvasive quantitative serologic methods were used. 86 patients (43 male and 43 female, mean age 50ą12 yrs.) with positive history of dyspeptic illness were included in study. The concentration of specific anti-HP IgG was measured in plasma of patients before, 2, 4 and 6 months after the treatment. Fresh plasma was frozen to -20°C until test was performed. We used ELISA Pyloriset EIA-G (Orion Diagnostica, Finland) with a cutoff titer of 300 mg/l. Results showed that the mean percentage of titer decrease was greatest two months after treatment (47%, p<0.001). A statistically significant decrease persisted after 4 and 6 months; 58% and 69% of titer before therapy, respectively p<0.001. According to some other authors, the titer should be monitored for 4 months to be sure that HP is eradicated. Unlike these studies, our results showed that in 11% of the patients seroconversion occurred (the patients whose titer declined by ł40% of the value measured before therapy) not earlier than after 6 months, so we recommend a 6-month monitoring.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
